People_

Dr Llew Mills

Division Addiction Medicine, Central Clinical School
South Eastern Sydney Local Health District, Drug and Alcohol Services

Phone

+61 421 032 614

Email

llew.mills@sydney.edu.au

Resume

Curriculum vitae

Biographical details

I am a drug and alcohol researcher with the University of Sydney Medical School, working at the Langton Centre, a drug and alcohol treatment and research centre in Surry Hills. I was also recently appointed as statistical consultant for the Drug and Alcohol Clinical Research Improvement Network (DACRIN).

Research interests

I am interested in:

1. The factors that cause and maintain addiction

2. The way that beliefs affect perceptions of withdrawal

3. Applied statistics and statistical methods (e.g. mixed-effects models, Bayesian statistics, machine learning)

4. The placebo and nocebo effect

5. Point of Care Trials

Teaching and supervision

Addiction medicine

Abnormal Psychology

Science and Statistics

Psychometrics and Individual Differences

Current projects

Comparing withdrawal from depot buprenorphine to withdrawal from sublingual buprenorphine in an inpatient population of opioid agonsit treatment seekers
A randomised placebo-controlled trial of nabiximols for the treatment of cannabis dependence.
The Clinical Outcomes and Quality Indicators (COQI) Project
The Cannabis as Medicine Survey (CAMS)
Exercise and Cannabis Withdrawal - an RCT testing the effect of exercise on cannabis withdrawal
Cannabidiol for Treatment of Alcohol Withdrawal
MA Data - Using electronic clinical information systems to assess outcomes for people being treated for methamphetamine dependence
Updating and validating the cannabis withdrawal scale (CWS)

Associations

Specialty of Addiction Medicine, Faculty of Medicine and Public Health, University of Sydney
Drug and Alcohol Services, South Eastern Sydney Local Health District
Drug and Alcohol Clinical Research and IMprovement Network (DACRIN)

Awards and honours

Travel Award, Society for Interdisciplinary Placebo Studies Conference (Leiden, The Netherlands, 2017)

Australian Postgraduate Award (2013-2016)

Themes

Neurosciences and Mental Health

Keywords

Quantitative psychology

Approaches

Clinical Trials, Translational Research, Treatment/Intervention

Publications

By Type

Expand all

Journals

Mills, L., Arnold, J., Suraev, A., Abelev, S., Zhou, C., Arkell, T., McGregor, I., Lintzeris, N. (2024). Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022–2023 (CAMS-22). Harm Reduction Journal, 21(1). [More Information]
Trevitt, B., Hayes, V., Deacon, R., Mills, L., Demirkol, A., Lintzeris, N. (2024). The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study. BMC Public Health, 24(1). [More Information]
Arkell, T., Abelev, S., Mills, L., Suraev, A., Arnold, J., Lintzeris, N., McGregor, I. (2023). Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey. Journal of Cannabis Research, 5(1). [More Information]
Black, E., Mammen, K., Deacon, R., Ezard, N., Mills, L., Dunlop, A., Montebello, M., Reid, D., Childs, S., Bruno, R., Lintzeris, N., et al (2023). Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug and Alcohol Review, 42(2), 389-400. [More Information]
Deacon, R., Mills, L., Bruno, R., Mammen, K., Dunlop, A., Childs, S., Shakeshaft, A., Holmes, J., Lintzeris, N. (2023). Identifying thresholds for clinically meaningful change among clients of drug and alcohol services using the Australian Treatment Outcomes Profile. Addiction, 118(12), 2457-2465. [More Information]
Suraev, A., Mills, L., Abelev, S., Arkell, T., McGregor, I., Lintzeris, N. (2023). Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nature and Science of Sleep, 15, 245-255. [More Information]
Mills, L., Lee, J., Boakes, R., Colagiuri, B. (2023). Reduction in caffeine withdrawal after open-label decaffeinated coffee. Journal of Psychopharmacology, 37(2), 181-191. [More Information]
Black, E., Bruno, R., Mammen, K., Mills, L., Siefried, K., Deacon, R., Shakeshaft, A., Dunlop, A., Ezard, N., Montebello, M., Lintzeris, N., et al (2023). Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study. Medical Journal of Australia, 219(5), 218-226. [More Information]
Chambers, M., Shakeshaft, A., Mills, L., Clifford-Motopi, A., Conigrave, J., Tran, A. (2023). Trajectories of Psychological Distress of Men Treated at Aboriginal Residential Rehabilitation Services for Alcohol and Drug Misuse. International Journal of Mental Health and Addiction. [More Information]
Mills, L., Dunlop, A., Montebello, M., Copeland, J., Bruno, R., Jefferies, M., McGregor, I., Lintzeris, N. (2022). Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Substance Abuse Treatment, Prevention, and Policy, 17(1). [More Information]
Mammen, K., Mills, L., Deacon, R., Bruno, R., Dunlop, A., Holmes, J., Luksza, J., Shakeshaft, A., Farrell, M., Lintzeris, N. (2022). Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review, 41(1), 106-113. [More Information]
Wilson, H., Schulz, M., Mills, L., Lintzeris, N. (2022). Feasibility and outcomes of a general practice and specialist alcohol and other drug collaborative care program in Sydney, Australia. Australian Journal of Primary Health, 28(2), 158-163. [More Information]
Lintzeris, N., Mills, L., Abelev, S., Suraev, A., Arnold, J., McGregor, I. (2022). Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduction Journal, 19(1). [More Information]
Montebello, M., Jefferies, M., Mills, L., Bruno, R., Copeland, J., McGregor, I., Rivas, C., Jackson, M., Silsbury, C., Dunlop, A., Lintzeris, N. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 234, 109388-1-109388-8. [More Information]
Lintzeris, N., Deacon, R., Hayes, V., Cowan, T., Mills, L., Parvaresh, L., Harvey Dodds, L., Jansen, L., Dojcinovic, R., Leung, M., et al (2022). Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug and Alcohol Review, 41(5), 1009-1019. [More Information]
Mills, L., Lintzeris, N., O'Malley, M., Arnold, J., McGregor, I. (2022). Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 41(5), 1095-1108. [More Information]
Coleshill, M., Baldwin, P., Black, M., Newby, J., Shrestha, T., Haffar, S., Mills, L., Stensel, A., Cockayne, N., Tennant, J., et al (2022). The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19. JMIR Research Protocols, 11(3). [More Information]
Monds, L., Bravo, M., Mills, L., Malcolm, A., Gilliver, R., Wood, W., Harrod, M., Read, P., Nielsen, S., Dietze, P., Lintzeris, N., et al (2022). The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review, 41(5), 1085-1094. [More Information]
Deacon, R., Mammen, K., Bruno, R., Mills, L., Dunlop, A., Holmes, J., Jefferies, M., Hall, M., Shakeshaft, A., Farrell, M., Lintzeris, N., et al (2021). Assessing the concurrent validity, inter-rater reliability and test–re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. Addiction, 116(5), 1245-1255. [More Information]
Lee, J., Mills, L., Hayes, B., Livesey, E. (2021). Modelling generalisation gradients as augmented Gaussian functions. The Quarterly Journal of Experimental Psychology, 74(1), 106-121. [More Information]
Deacon, R., Mammen, K., Holmes, J., Dunlop, A., Bruno, R., Mills, L., Graham, R., Lintzeris, N. (2020). Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review, 39(5), 441-446. [More Information]
Lintzeris, N., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Kirby, A., Montebello, M., Hall, M., Jefferies, M., Kevin, R., Bhardwaj, A. (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 215, 108220. [More Information]
Lintzeris, N., Mills, L., Suraev, A., Bravo, M., Arkell, T., Arnold, J., Benson, M., McGregor, I. (2020). Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 17(1), 37. [More Information]
Mills, L., Lintzeris, N., Bruno, R., Montebello, M., Dunlop, A., Deacon, R., Copeland, J., Jefferies, M., Rivas, C., Mammen, K. (2020). Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review, 39(4), 356-364. [More Information]
Lintzeris, N., Bhardwaj, A., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Gugusheff, J., Phung, N., Montebello, M., Kirby, A., Allsop, D., et al (2019). Nabiximols for the Treatment of Cannabis Dependence A Randomized Clinical Trial. JAMA Internal Medicine, 179(9), 1242-1253. [More Information]
Mills, L., Boakes, R., Colagiuri, B. (2019). The effect of dose expectancies on caffeine withdrawal symptoms during tapered dose reduction. Journal of Psychopharmacology, 33(8), 994-1002. [More Information]
Norberg, M., Newins, A., Crone, C., Ham, L., Henry, A., Mills, L., Dennis, P. (2019). Why are caffeinated alcoholic beverages especially risky? Addictive Behaviors, 98, 1-6. [More Information]
Meiser, B., Quinn, V., Mitchell, G., Tucker, K., Watts, K., Rahman, B., Peate, M., Saunders, C., Geelhoed, E., Gleeson, M., Barlow-Stewart, K., Bowen, M., Kirk, J., et al (2018). Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history. European Journal of Human Genetics, 26(7), 972-983. [More Information]
Mills, L., Dar-Nimrod, I., Colagiuri, B. (2017). Effect of Genetic Information and Information About Caffeine Content on Caffeine Withdrawal Symptoms. Scientific Reports, 7(1), 1-9. [More Information]
Norberg, M., Newins, A., Mills, L., Ham, L. (2017). Psychometric Validation of the Anticipated Effects of Alcohol Mixed With Energy Drinks Scale. Psychological Assessment, 29(12), 1505-1516. [More Information]
Mills, L., Boakes, R., Colagiuri, B. (2016). Placebo caffeine reduces withdrawal in abstinent coffee drinkers. Journal of Psychopharmacology, 30(4), 388-394. [More Information]

show 28 more

By Year

Expand all

2024

Mills, L., Arnold, J., Suraev, A., Abelev, S., Zhou, C., Arkell, T., McGregor, I., Lintzeris, N. (2024). Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022–2023 (CAMS-22). Harm Reduction Journal, 21(1). [More Information]
Trevitt, B., Hayes, V., Deacon, R., Mills, L., Demirkol, A., Lintzeris, N. (2024). The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study. BMC Public Health, 24(1). [More Information]

2023

Arkell, T., Abelev, S., Mills, L., Suraev, A., Arnold, J., Lintzeris, N., McGregor, I. (2023). Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey. Journal of Cannabis Research, 5(1). [More Information]
Black, E., Mammen, K., Deacon, R., Ezard, N., Mills, L., Dunlop, A., Montebello, M., Reid, D., Childs, S., Bruno, R., Lintzeris, N., et al (2023). Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug and Alcohol Review, 42(2), 389-400. [More Information]
Deacon, R., Mills, L., Bruno, R., Mammen, K., Dunlop, A., Childs, S., Shakeshaft, A., Holmes, J., Lintzeris, N. (2023). Identifying thresholds for clinically meaningful change among clients of drug and alcohol services using the Australian Treatment Outcomes Profile. Addiction, 118(12), 2457-2465. [More Information]
Suraev, A., Mills, L., Abelev, S., Arkell, T., McGregor, I., Lintzeris, N. (2023). Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nature and Science of Sleep, 15, 245-255. [More Information]
Mills, L., Lee, J., Boakes, R., Colagiuri, B. (2023). Reduction in caffeine withdrawal after open-label decaffeinated coffee. Journal of Psychopharmacology, 37(2), 181-191. [More Information]
Black, E., Bruno, R., Mammen, K., Mills, L., Siefried, K., Deacon, R., Shakeshaft, A., Dunlop, A., Ezard, N., Montebello, M., Lintzeris, N., et al (2023). Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study. Medical Journal of Australia, 219(5), 218-226. [More Information]
Chambers, M., Shakeshaft, A., Mills, L., Clifford-Motopi, A., Conigrave, J., Tran, A. (2023). Trajectories of Psychological Distress of Men Treated at Aboriginal Residential Rehabilitation Services for Alcohol and Drug Misuse. International Journal of Mental Health and Addiction. [More Information]

show 4 more

2022

Mills, L., Dunlop, A., Montebello, M., Copeland, J., Bruno, R., Jefferies, M., McGregor, I., Lintzeris, N. (2022). Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Substance Abuse Treatment, Prevention, and Policy, 17(1). [More Information]
Mammen, K., Mills, L., Deacon, R., Bruno, R., Dunlop, A., Holmes, J., Luksza, J., Shakeshaft, A., Farrell, M., Lintzeris, N. (2022). Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review, 41(1), 106-113. [More Information]
Wilson, H., Schulz, M., Mills, L., Lintzeris, N. (2022). Feasibility and outcomes of a general practice and specialist alcohol and other drug collaborative care program in Sydney, Australia. Australian Journal of Primary Health, 28(2), 158-163. [More Information]
Lintzeris, N., Mills, L., Abelev, S., Suraev, A., Arnold, J., McGregor, I. (2022). Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduction Journal, 19(1). [More Information]
Montebello, M., Jefferies, M., Mills, L., Bruno, R., Copeland, J., McGregor, I., Rivas, C., Jackson, M., Silsbury, C., Dunlop, A., Lintzeris, N. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 234, 109388-1-109388-8. [More Information]
Lintzeris, N., Deacon, R., Hayes, V., Cowan, T., Mills, L., Parvaresh, L., Harvey Dodds, L., Jansen, L., Dojcinovic, R., Leung, M., et al (2022). Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug and Alcohol Review, 41(5), 1009-1019. [More Information]
Mills, L., Lintzeris, N., O'Malley, M., Arnold, J., McGregor, I. (2022). Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 41(5), 1095-1108. [More Information]
Coleshill, M., Baldwin, P., Black, M., Newby, J., Shrestha, T., Haffar, S., Mills, L., Stensel, A., Cockayne, N., Tennant, J., et al (2022). The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19. JMIR Research Protocols, 11(3). [More Information]
Monds, L., Bravo, M., Mills, L., Malcolm, A., Gilliver, R., Wood, W., Harrod, M., Read, P., Nielsen, S., Dietze, P., Lintzeris, N., et al (2022). The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review, 41(5), 1085-1094. [More Information]

show 6 more

2021

Deacon, R., Mammen, K., Bruno, R., Mills, L., Dunlop, A., Holmes, J., Jefferies, M., Hall, M., Shakeshaft, A., Farrell, M., Lintzeris, N., et al (2021). Assessing the concurrent validity, inter-rater reliability and test–re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. Addiction, 116(5), 1245-1255. [More Information]
Lee, J., Mills, L., Hayes, B., Livesey, E. (2021). Modelling generalisation gradients as augmented Gaussian functions. The Quarterly Journal of Experimental Psychology, 74(1), 106-121. [More Information]

2020

Deacon, R., Mammen, K., Holmes, J., Dunlop, A., Bruno, R., Mills, L., Graham, R., Lintzeris, N. (2020). Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review, 39(5), 441-446. [More Information]
Lintzeris, N., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Kirby, A., Montebello, M., Hall, M., Jefferies, M., Kevin, R., Bhardwaj, A. (2020). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 215, 108220. [More Information]
Lintzeris, N., Mills, L., Suraev, A., Bravo, M., Arkell, T., Arnold, J., Benson, M., McGregor, I. (2020). Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 17(1), 37. [More Information]
Mills, L., Lintzeris, N., Bruno, R., Montebello, M., Dunlop, A., Deacon, R., Copeland, J., Jefferies, M., Rivas, C., Mammen, K. (2020). Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review, 39(4), 356-364. [More Information]

show 1 more

2019

Lintzeris, N., Bhardwaj, A., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Gugusheff, J., Phung, N., Montebello, M., Kirby, A., Allsop, D., et al (2019). Nabiximols for the Treatment of Cannabis Dependence A Randomized Clinical Trial. JAMA Internal Medicine, 179(9), 1242-1253. [More Information]
Mills, L., Boakes, R., Colagiuri, B. (2019). The effect of dose expectancies on caffeine withdrawal symptoms during tapered dose reduction. Journal of Psychopharmacology, 33(8), 994-1002. [More Information]
Norberg, M., Newins, A., Crone, C., Ham, L., Henry, A., Mills, L., Dennis, P. (2019). Why are caffeinated alcoholic beverages especially risky? Addictive Behaviors, 98, 1-6. [More Information]

2018

Meiser, B., Quinn, V., Mitchell, G., Tucker, K., Watts, K., Rahman, B., Peate, M., Saunders, C., Geelhoed, E., Gleeson, M., Barlow-Stewart, K., Bowen, M., Kirk, J., et al (2018). Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history. European Journal of Human Genetics, 26(7), 972-983. [More Information]

2017

Mills, L., Dar-Nimrod, I., Colagiuri, B. (2017). Effect of Genetic Information and Information About Caffeine Content on Caffeine Withdrawal Symptoms. Scientific Reports, 7(1), 1-9. [More Information]
Norberg, M., Newins, A., Mills, L., Ham, L. (2017). Psychometric Validation of the Anticipated Effects of Alcohol Mixed With Energy Drinks Scale. Psychological Assessment, 29(12), 1505-1516. [More Information]

2016

Mills, L., Boakes, R., Colagiuri, B. (2016). Placebo caffeine reduces withdrawal in abstinent coffee drinkers. Journal of Psychopharmacology, 30(4), 388-394. [More Information]

Selected Grants

2022

A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence, Lintzeris N, Lubman D, Doyle M, Dunlop A, Mills L, Harrod M, Arunogiri S, Malouf P, Haber P, Freeman T, Haber P, National Health and Medical Research Council (NHMRC)/Clinical Trials and Cohort Studies

2019

Externally funded position - For Dr Llewellyn Mills, Mills L, South Eastern Sydney Local Health District/Externally Funded Position

Techinical Skills

Advanced statistical skills, including machine learning (e.g. penalised regression, random forests), ROC analysis, survival analysis, scale validation, mixed-effects modeling (incl. non-linear) and Bayesian statistics.

Advanced skills in R(analysis,preprocessing,visualisation,computationalmodelling),working skills in Python, Stata, SPSS. Advanced skills in Redcap survey software.

In the media

- Phone interview with Stephen Brooke, reported in Sunday Age and Sydney Morning Herald, see https://www.smh.com.au/healthcare/more-acceptable-now-medicinal-cannabis-use-rising-passes-1-million-patients-20230511-p5d7oe.html

- Phone Interviews: Sydney drive time, 14/02/2023, Zoom interview with Mateusz Mroz (Newseria: Polish Private News Agency Website) 15/02/2023; ABC Radio Wollongong Breakfast drivetime with Melinda James, 15/02/2023; ABC Radio Canberra. Afternoons with Alice Matthews, 15/02/2023; ABC Radio Melbourne Drive: Raph Epstein, 15/02/2023; ABC Radio Tasmania. Evenings with Helen Shield (statewide), 15/02/2023; ABC Radio Canberra: Canberra Weekender with Tatjana Clancy, 18/02/2023; ChaiFM South Africa: Morning Mayhem with Howard Feldman, 23/03/2023

- Answering interview questions via email

o Nancy Schimelpfening (Healthline: 16/02/2023 https://www.healthline.com/health-news/caffeine-withdrawal-drinking-decaf-can-help-reduce-painful-symptoms

o Robby Berman (Healthline: 16/02/2023; see https://www.medicalnewstoday.com/articles/caffeine-withdrawal-good-decaf-coffee-reduce-symptoms#What-caused-the-effect)

o Shiv Sudhakar (Fox News Digital, health and lifestyle, see https://www.foxnews.com/health/coffee-quitters-help-decaf-help-reduce-withdrawal-symptoms) 20/02/23

o Imma Perfetto, Cosmos magazine, 16/02/23 see https://cosmosmagazine.com/health/decaf-coffee-caffeine-withdrawal/

o Cara Murez, USNEWS, see https://www.usnews.com/news/health-news/articles/2023-02-17/kicking-the-coffee-habit-but-scared-of-withdrawal-try-decaf

o Matthew Warren, British Psychological Society website, see https://www.bps.org.uk/research-digest/decaf-coffee-reduces-caffeine-withdrawal-even-when-you-know-its-decaf

- Phone Interviews:ABC News Radio: Morning Show with Sarah Morice, 08/12/2023; ABC Radio Canberra with Georgia Stynes, 11/12/2023; ABC Radio Darwin with Lisa Pellegrino 11/12/2023;

- Answering questions by email:

o ABC News website: https://www.abc.net.au/news/health/2023-12-08/caffeine-withdrawal-headache-coffee-brain-neurobiology-adenosine/103173730

ABC Life Article: Can you be addicted to coffee and is it really bad for you? 02 May, 2019, see https://www.abc.net.au/everyday/coffee-addiction-how-much-is-too-much-withdrawal-symptoms/11028304

Weekend Australian Article, 23-24 April, 2016 (see CV Docs)

Faculty of Medicine and Health

Page not found